Compare AMSS & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSS | HCWB |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.6M |
| IPO Year | 2026 | 2021 |
| Metric | AMSS | HCWB |
|---|---|---|
| Price | $0.24 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.0K | ★ 86.1K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | $3.71 | $12,215.61 |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.86 |
| 52 Week High | $2.44 | $23.94 |
| Indicator | AMSS | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 29.50 | 30.32 |
| Support Level | N/A | $0.86 |
| Resistance Level | $0.39 | $1.73 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 18.97 | 3.71 |
Amass Brands Inc is building a diversified premium beverage platform at the intersection of craft, wellness, and functionality. The company operates in the beverage industry, offering a portfolio that includes spirits, wine, and non-alcoholic products. The company distributes its brands in the United States through wholesale, on-premise, and direct-to-consumer channels. The company has two segments: Wine and Spirits. The majority of the company's revenue is derived from the Wine segment, which offers a portfolio of premium imported and domestic wine brands. Geographically, it operates predominantly in the USA.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.